Emerging therapies for cerebrovascular disorders.
Fisher
Marc
M
Department of Neurology, University of Massachusetts Medical School, Worcester 01605, USA. fisherm@ummhc.org
Davalos
Antonio
A
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000069059:Atorvastatin; D002560:Cerebrovascular Circulation / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000517:prevention & control; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy; D002532:Intracranial Aneurysm / Q000601:surgery / Q000628:therapy; D011758:Pyrroles / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012306:Risk; D019821:Simvastatin / Q000627:therapeutic use; D013812:Therapeutics / Q000639:trends*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin; D010959:Tissue Plasminogen Activator